Methylation protects dietary flavonoids from rapid hepatic metabolism

Abstract

The metabolic stability of two potential cancer chemopreventive flavones, i.e. 5,7-dimethoxyflavone (5,7-DMF) and 3′,4′-dimethoxyflavone (3′,4′-DMF), compared with the non-methylated flavone galangin (3,5,7-trihydroxyflavone), was investigated in human hepatic preparations. Galangin, as expected, was extensively metabolized mainly by glucuronidation in human liver S9 fractions in the presence of appropriate co-factors. In contrast, 5,7-DMF and 3′,4′-DMF were metabolically highly stable with only a small fraction of 3′,4′-DMF undergoing oxidation. Consistent with the S9 fraction results, galangin was almost completely depleted after 2-h incubations in freshly plated hepatocytes. The hepatocytes also showed some metabolism of 3′,4′-DMF, but virtually none of 5,7-DMF. In human liver microsomes, 5,7-DMF was more metabolically stable than 3′,4′-DMF. The observations present a new strategy for examining the metabolic stability of dietary flavonoids and suggest that methylated flavonoids may have a high oral bioavailability compared with their non-methylated forms, which will make them more likely to be useful as cancer chemoprotectants.

Key words::

• Methylated flavones
• hepatic metabolism
• bioavailability

Acknowledgements

The study was supported by the Department of Defense/Hollings Cancer Center (Grant No. N6311602MD200) and by the National Institutes of Health (Grant No. GM55561). It was also partially supported by a grant from the American Institute for Cancer Research. U. Kristina Walle is highly acknowledged for her efforts and skills in the preparation of the manuscript.